
An administrative court in Italy today scrapped a €173.3 million ($170.4 million) fine leveled at Apple and Amazon last year for alleged anti-competitive cooperation when selling Apple and Beats products, Reuters reports.
In November 2021, Italy’s antitrust watchdog hit Apple and Amazon with a $196 million fine in the culmination of an investigation that began in 2020 over allegations that the two companies had been blocking the sale of Apple and Beats devices to resellers in order to stifle competition and keep prices high.
The regulator said contractual provisions of a 2018 agreement between the two companies meant only selected resellers were allowed to sell the products on Amazon’s Italian store, which was in violation of EU rules and affected competition on prices.
Amazon was fined €68.7 million euros ($67.6 million), while Apple received a fine of $132.3 million. The watchdog also ordered the companies to end the restrictions to give retailers of genuine Apple and Beats products access to the Italian Amazon web store in a “non-discriminatory manner.”
Both Apple and Amazon appealed against the fines. “To ensure our customers purchase genuine products, we work closely with our reseller partners and have dedicated teams of experts around the world who work with law enforcement, customs and merchants to ensure only genuine Apple products are being sold,” Apple said, denying any wrongdoing. In a separate statement Amazon said it strongly disagreed with the decision of the Italian authority and that the proposed fine was “disproportionate and unjustified.”
Earlier this year, the fine was reduced to an overall €173.3 million ($170.4 million) due to a “material error” in the initial calculation. Amazon welcomed today’s ruling in a statement, while Apple and Italy’s antitrust regulator declined to comment.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas